Drugs that contain Allopurinol; Lesinurad
1. List of Duzallo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8003681 | IRONWOOD PHARMS INC | 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester |
Aug, 2025
(2 years from now) | |
| US8546436 | IRONWOOD PHARMS INC | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
Feb, 2032
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10183012 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(5 years from now) | |
| US8283369 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(5 years from now) | |
| US8546437 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Apr, 2029
(5 years from now) | |
| US8084483 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Aug, 2029
(6 years from now) | |
| US8357713 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Dec, 2029
(6 years from now) | |
| US9216179 | IRONWOOD PHARMS INC | Treatment of gout and hyperuricemia |
Aug, 2031
(8 years from now) | |
| US9956205 | IRONWOOD PHARMS INC | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
Dec, 2031
(8 years from now) | |
Market Authorisation Date: 18 August, 2017
Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone
Dosage: TABLET;ORAL
DUZALLO family patents
62
United States
13
European Union
11
Japan
9
China
7
Korea, Republic of
7
New Zealand
7
EA
7
Australia
7
South Africa
6
Canada
6
Brazil
5
Spain
5
Mexico
5
Israel
4
Poland
4
Slovenia
4
Ukraine
4
Hong Kong
4
Taiwan
4
Lithuania
4
RS
4
Denmark
4
Croatia
4
Hungary
4
Portugal
4
Singapore
4
Cyprus
3
ME
3
Argentina
2
Chile
2
Luxembourg
2
Malaysia
2
Norway
2
Austria
2
Ecuador
1
Turkey
1
Morocco
1
Netherlands
1
India
1
Colombia
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic